Clinical Trial Update: An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment

View source ↗

Summary

An observational study evaluating outcomes in patients with Type 2 diabetes initiating NovoMix 30 insulin; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoMix 30 (insulin aspart protamine fixed-dose combination)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Status: COMPLETED